for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Intra-Cellular Therapies Inc

ITCI.OQ

Latest Trade

25.59USD

Change

0.08(+0.31%)

Volume

172,981

Today's Range

25.30

 - 

26.04

52 Week Range

8.90

 - 

43.56

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
25.51
Open
25.51
Volume
172,981
3M AVG Volume
40.52
Today's High
26.04
Today's Low
25.30
52 Week High
43.56
52 Week Low
8.90
Shares Out (MIL)
80.16
Market Cap (MIL)
2,044.82
Forward P/E
-7.70
Dividend (Yield %)
--

Next Event

Q4 2020 Intra-Cellular Therapies Inc Earnings Release

Latest Developments

More

Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results And Provides Corporate Update

Intra-Cellular Therapies Prices Public Offering Of Common Stock

Intra-Cellular Therapies Delivers Written Notice To Svb Leerink To Terminate Sales Agreement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).

Industry

Biotechnology & Drugs

Contact Info

430 E 29th St

NEW YORK, NY

10016-8367

United States

+1.212.9233344

http://www.intracellulartherapies.com/

Executive Leadership

Lawrence J. Hineline

Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary

Michael I. Halstead

Executive Vice President, General Counsel and Secretary

Mark Neumann

Executive Vice President, Chief Commercial Officer

Robert E. Davis

Senior Vice President and Chief Scientific Officer

John A. Bardi

Senior Vice President - Market Access, Policy and Government Affairs

Key Stats

1.50 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-2.120

2018

-2.840

2019

-2.680

2020(E)

-3.320
Price To Earnings (TTM)
--
Price To Sales (TTM)
196.25
Price To Book (MRQ)
2.88
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-42.20
Return on Equity (TTM)
-39.34

Latest News

Latest News

BRIEF-Intra-Cellular Therapies Announces Positive Results From Study In Patients With Heart Failure

* INTRA-CELLULAR THERAPIES ANNOUNCES POSITIVE TOP-LINE RESULTS FROM ITI-214 PHASE I/II STUDY IN PATIENTS WITH HEART FAILURE

BRIEF-Intra-Cellular Therapies Q1 Loss Per Share $0.73

* INTRA-CELLULAR THERAPIES REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Intra-Cellular Therapies Initiates Promotional Activities For Caplyta (Lumateperone) For The Treatment Of Schizophrenia In Adults

* INTRA-CELLULAR THERAPIES INITIATES PROMOTIONAL ACTIVITIES FOR CAPLYTA™ (LUMATEPERONE) FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS Source text for Eikon: Further company coverage:

BRIEF-Intra-Cellular Says Wholesale Acquisition Price For Caplyta Is $1,320/Month

* INTRA-CELLULAR THERAPIES - WHOLESALE ACQUISITION PRICE FOR CAPLYTA (LUMATEPERONE) IS $1320 PER MONTH Further company coverage:

BRIEF-Intra-Cellular Therapies Announces Availability Of Caplyta™ For Adult Patients With Schizophrenia

* INTRA-CELLULAR THERAPIES ANNOUNCES AVAILABILITY OF CAPLYTA™ (LUMATEPERONE) FOR ADULT PATIENTS WITH SCHIZOPHRENIA

Intra-Cellular prices schizophrenia drug at $1,320 per month

Intra-Cellular Therapies Inc said on Monday its lead drug to treat schizophrenia was now available at U.S. pharmacies for a list price of $1,320 a month.

BRIEF-Intra-Cellular Therapies Outbreak Of Novel Strain Of Coronavirus Could Have A Material Adverse Impact On Co

* INTRA-CELLULAR THERAPIES INC - OUTBREAK OF NOVEL STRAIN OF CORONAVIRUS COULD HAVE A MATERIAL ADVERSE IMPACT ON CO

BRIEF-Intra-Cellular Therapies Reports Q4 Loss Per Share Of $0.74

* INTRA-CELLULAR THERAPIES REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF- Intra-Cellular Therapies Announces Publication Of Results From CAPLYTA Clinical Trial

* PIVOTAL STUDY OF CAPLYTA™ (LUMATEPERONE) FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS PUBLISHED IN JAMA PSYCHIATRY Source text for Eikon: Further company coverage:

FDA approves Intra-Cellullar's schizophrenia drug, shares soar 85%

Intra-Cellular Therapies Inc said on Monday its lead drug to treat schizophrenia in adults has received approval from the U.S. Food and Drug Administration, sending its shares soaring 85%.

Intra-Cellular drug fails bipolar depression study; shares fall 14%

Intra-Cellular Therapies Inc said on Monday its lead drug failed to meet the main goal of a late-stage study in patients with major depressive episodes associated with bipolar disorder.

Intra-Cellular drug fails one of two bipolar depression studies

Intra-Cellular Therapies Inc said on Monday its experimental treatment failed to meet the main goal of one of two studies in patients with major depressive episodes associated with bipolar disorder.

BRIEF-Intra-Cellular Therapies Reports Q1 Loss Per Share $0.65

* INTRA-CELLULAR THERAPIES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Intra-Cellular Therapies Announces Positive Pre-NDA Meeting With FDA For Schizophrenia Treatment

* INTRA-CELLULAR THERAPIES ANNOUNCES POSITIVE PRE-NDA MEETING WITH FDA FOR LUMATEPERONE FOR THE TREATMENT OF SCHIZOPHRENIA

BRIEF-Intra-Cellular Therapies Reports Q4 Loss Per Share $0.56

* INTRA-CELLULAR THERAPIES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Intra-Cellular Therapies receives FDA fast track designation for Schizophrenia treatment drug

* Intra-Cellular Therapies receives FDA fast track designation for lumateperone for the treatment of schizophrenia

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up